Cargando…

KEYNOTE‐025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1–positive advanced non–small‐cell lung cancer

Pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD‐1), has been shown to improve overall survival (OS) in patients with previously treated advanced non–small‐cell lung cancer (NSCLC) with programmed death ligand 1 (PD‐L1) tumor proportion score (TPS) ≥1%. We report safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, Makoto, Takahashi, Toshiaki, Yoshioka, Hiroshige, Nakagawa, Kazuhiko, Fukuhara, Tatsuro, Yamada, Kazuhiko, Ichiki, Masao, Tanaka, Hiroshi, Seto, Takashi, Sakai, Hiroshi, Kasahara, Kazuo, Satouchi, Miyako, Han, Shi Rong, Noguchi, Kazuo, Shimamoto, Takashi, Kato, Terufumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398876/
https://www.ncbi.nlm.nih.gov/pubmed/30618179
http://dx.doi.org/10.1111/cas.13932